Does anthracycline administration by infusion in children affect late cardiotoxicity?

Area of Science:

• Pediatric Oncology
• Cardiology
• Pharmacology

Background:

• Anthracyclines are effective chemotherapy agents for childhood cancers like acute lymphoblastic leukemia (ALL).
• Late cardiotoxicity is a significant concern following anthracycline treatment, often dose-dependent.
• Infusion administration aims to reduce peak drug concentrations and potentially mitigate cardiotoxicity.

Purpose of the Study:

• To compare the late cardiotoxicity of anthracycline administration by bolus injection versus 6-hour infusion in childhood ALL survivors.
• To assess cardiac performance using echocardiography in these patient groups.

Main Methods:

• Retrospective analysis of relapse-free survivors of childhood ALL treated with a cumulative daunorubicin dose of 180 mg/m2.
• Two treatment arms: bolus injection (UKALL X, n=40) and 6-hour infusion (UKALL XI, n=71).
• Cardiac function assessed by echocardiography with a follow-up of approximately 5.4 years.

Main Results:

• Both bolus and infusion groups exhibited similar, mild impairment in cardiac performance.
• Key indicators of cardiac dysfunction included increased left ventricular end-systolic stress and reduced left ventricular function.
• Subclinical left ventricular performance abnormalities were present in all survivors, irrespective of administration method.

Conclusions:

• A 6-hour infusion of anthracyclines did not demonstrate an advantage over bolus injection in reducing late cardiotoxicity at a cumulative dose of 180 mg/m2.
• Mild subclinical cardiac dysfunction is a common finding in childhood ALL survivors treated with this anthracycline dose.
• Further research may be needed to explore alternative strategies for cardiotoxicity prevention.